Current approaches to the treatment of pulmonary arterial hypertension: prospects for disease modification and therapeutic strategies

Pulmonary arterial hypertension (PAH) is a progressive disease accompanied by proliferative remodeling of the pulmonary arteries. Despite the obvious advances in its treatment that have occurred recently, the mortality associated with PAH remains high. We present a review of modern Russian and foreign literature devoted to the problem of PAH and the search for methods to solve it. The following resources were used in our review: Russian Science Citation Index, Best Evidence, Scopus, Elsevier, PubMed, Clinical Evidence, Cochrane Library. Therapeutic strategies that have a potency for modification of the disease are presented. Among the novel drugs, two seem to be particularly promising since they have potent disease-modifying properties: sotatercept, which targets the TGF-β superfamily pathway, and seralutinib, an inhaled PDGFR inhibitor. Although sotatercept has demonstrated great efficacy, seralutinib has a potential for the combined therapy use.